Glaukos Corp (GKOS) said Monday that the US Food and Drug Administration has accepted its corneal disease drug Epioxa for review, with a goal date of Oct. 10.
Epioxa is a corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease.
The application includes data from two phase 3 pivotal trials of Epioxa, which both successfully achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。